Saturday, December 20, 2014

Teva turmoil gets worse as CEO Jeremy Levin departs

The turmoil at Teva Pharmaceutical Industries, Ltd., reached a new high Wednesday morning when the company announced that Chief Executive Officer Jeremy Levin "has agreed" with the board of directors to step down.

Teva turmoil gets worse as CEO Jeremy Levin departs

Jeremy Levin has stepped down as CEO of Teva
Jeremy Levin has stepped down as CEO of Teva

 The turmoil at Teva Pharmaceutical Industries, Ltd., reached a new high Wednesday morning when the company announced that Chief Executive Officer Jeremy Levin "has agreed" with the board of directors to step down.

Levin was hired on Jan. 1, 2012 and didn't start until May of 2012. The company is based in Israel, but has big operations in suburban Philadelphia. Chief Financial Officer Eyal Desheh will take over as interim CEO.

Teva's statement is here:

JERUSALEM--(BUSINESS WIRE)--Oct. 30, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its Board of Directors has agreed with Dr. Jeremy Levin that he will step down as President and Chief Executive Officer. The Board has named Eyal Desheh, Teva's Executive Vice President and Chief Financial Officer, to fill the role of President and Chief Executive Officer on an interim basis, effective immediately, and it has formed a committee that will promptly begin to search for a permanent successor.

More coverage
 
Nutter heads to Tel Aviv, a global tech hub
 
Teva to cut 5,000 jobs by end of 2014
 
Teva renews leases for buildings in Philly suburbs of Montgomery and Bucks counties
 
Teva shareholders OK CEO's $4.5M pay package despite criticism
 
Moody's report says generic drug companies face greater challenges
 
Legal bills lead to Teva's 2Q loss, possible settlement
 
Teva's profit prospects hurt by appeals court decision on Copaxone
 
Teva CEO Jeremy Levin in line for $3.7 million in pay for 2012

Dr. Phillip Frost, Chairman of the Board, stated “On behalf of the entire Board of Directors, I would like to thank Dr. Jeremy Levin for his meaningful contribution to Teva during the last two years. The Board and management team are fully committed to the implementation of Teva's strategy, including the development of new compounds, making strategic acquisitions, forming joint ventures and the planned acceleration of the Company’s cost reduction program.”

“Since I joined Teva, we have made tremendous progress in setting a new course for the Company,” said Dr. Jeremy Levin. "I wish the Company and its people, who I respect greatly, every success. I look forward to pursuing new opportunities where I can continue to apply my experience and contribute to the evolution of the global pharmaceutical industry.”

"I have full confidence in the ability of Teva's management and employees to achieve our goals and execute the strategy laid out for the Company,” said Eyal Desheh, who has served at Teva for over 12 years, including the last five as Chief Financial Officer. “My colleagues in Teva's management and I will continue to drive execution and results in full collaboration with our Board of Directors, for the benefit of our patients, shareholders, customers and employees."

 As previously scheduled, Teva will report its third quarter 2013 financial results on October 31, 2013.

David Sell
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Business Videos:
Also on Philly.com:
Stay Connected